Telangana has set an ambitious goal to attract $25 billion in investments, generate five lakh jobs, and transform Hyderabad into a "Laboratory of the Future", a global hub for innovation-led life sciences growth, over the next five years.
The state unveiled these plans at the BioAsia 2026 conference which got underway here on Tuesday. Under the theme "TechBio Unleashed: AI, Automation & the Biology Revolution," the two-day event examines how AI, advanced biology, and intelligent manufacturing are converging to transform therapy discovery, development, and delivery worldwide.
BioAsia 2026 drew record participation, with over 4,000 delegates from 500 top life sciences companies worldwide.
Chief Minister A Revanth Reddy presented the Genome Valley Excellence Award to Prof Bruce Levine, renowned professor from the University of Pennsylvania.
Speaking on the occasion, the CM shared an insight into the recent launch of Telangana Next-Gen Life Sciences Policy at Davos, the expansion of Genome Valley, launch of 1Bio or world-class research and innovation, the acceleration of Green Pharma City, and opening of various global capability centres in Hyderabad.
“In the last two years, Telangana received investments worth over Rs 73,000 crore in the life sciences sector,” he said, adding that Hyderabad had emerged as the preferred destination to set up GCCs, build innovation engines, design molecules and drugs, AI platforms and drive digital manufacturing.
IT and Industries Minister Duddilla Sridhar Babu said the state government was aiming to attract investments worth USD 25 billion in the life sciences sector by 2030 and generate five lakh new jobs.
The Telangana Next-Gen Life Sciences Policy (2026-2030) was formulated to position the state among the top three life sciences clusters globally by the end of this decade. A dedicated policy has also been introduced to develop Hyderabad as a global medical tourism hub, he said.
Also read: A fine balance between equity and rewarding performance
Telangana is committed to positioning itself as a preferred global hub for life sciences, leveraging strategic initiatives and collaborative efforts to foster innovation, research, and development, the Minister said.
At Bio Asia 2026, major announcements were made by Opella Healthcare (France), Vaksindo Animal Health Pvt Ltd (division of JAPFA, Indonesia), Tredence Inc (USA), and Rx Propellant (RxP). The Swiss Pharmaceutical giant, Novartis unveiled a logo celebrating 25 years of its GCC presence in India with Hyderabad as its largest centre globally outside its headquarters in Basel, Switzerland.
On the sidelines of the conference, the Chief minister met the leadership teams from Miltenyi Biotec, Sanofi, MSD, Takeda along with the Consul General of Indonesia and team from Vaksindo, Indonesia.
“Telangana has established itself as a global leader in life sciences, pharmaceuticals, and healthcare. The Next Gen Life Sciences Policy 2026-30 emphasises that future growth will be driven by cross-border collaboration, international capital, and shared innovation. This reflects the state's dedication to innovation and excellence. Telangana is developing a future-ready ecosystem that transforms scientific breakthroughs into practical healthcare solutions for India and the global community. This strategy aims to foster sustainable economic growth and reinforce the state's leadership in the global life sciences sector,” Revanth said.
Opella Healthcare, a global consumer healthcare company, announced plans to expand its GCC operations here in a 42,000 sq. ft. facility, creating up to 500 jobs within the next year.
Similarly, Vaksindo Animal Health Pvt Ltd, a division of JAPFA Indonesia, is establishing a state-of-the-art BSL-3 vaccine manufacturing facility in Genome Valley On the outskirts of Hyderabad. The facility will focus on producing vaccines for poultry, cattle, swine, and aquaculture.
Tredence Inc, an AI and data science company, announced its Hyderabad operations as a dedicated innovation hub focused on AI-driven healthcare and life sciences analytics. The facility will span approximately 18,000 sq. ft. and support its global operations.
Rx Propellant (RxP) to develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India’s life sciences ecosystem. The project will comprise over 1 million square feet of advanced laboratory infrastructure spread across 12 acres of site delivered in phases over the next six years.
Follow us
